KYS 05090

Known as: KYS-05090, KYS05090 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2014
0120072014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Four positively charged compounds, previously shown to produce analgesic activity by interacting with prokineticin receptor or T… (More)
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2014
2014
It has been reported that [3-(1,1'-biphenyl-4-yl)-2-(1-methyl-5-dimethylamino-pentylamino)-3,4-dihydroquinazolin-4-yl]-N… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2013
2013
The growth inhibition of human cancer cells via T-type Ca(2+) channel blockade has been well known. Herein, a series of new 3,4… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2012
2012
An extension of our previously reported 3,4-dihydroquinazoline derivative is investigated. Oral anti-tumoral activity of 3,4… (More)
Is this relevant?
2010
2010
A comparative molecular similarity indices analysis (CoMSIA) of a set of 42 3,4-dihydroquinazolines have been performed to find… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2008
2008
In order to further clarify the role of T-type Ca(2+) channels in cell proliferation, we have measured the growth inhibition of… (More)
Is this relevant?
2007
2007
The intensive SAR study of 3,4-dihydroquinazoline series led to the most potent compound 10 (KYS05090: IC(50)=41+/-1 nM) against… (More)
Is this relevant?